Company Overview and News
KUALA LUMPUR (Aug 27): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Aug 28) may include Daiman Development Bhd, Gamuda Bhd, Taliworks Corp Bhd, Top Glove Corp Bhd, Matrix Concepts Holdings Bhd, Vertice Bhd, BIMB Holdings Bhd, IOI Properties Group Bhd, Utusan Melayu (Malaysia) Bhd, WCT Holdings Bhd and Watta Holding Bhd.
7240 7113 TPGVF 9679 7226 5355 TGLVY 5249 5754 5258 5236 BSMAF 1818
KUALA LUMPUR (Aug 27): Vertice Bhd, formerly known as Voir Holdings Bhd, has bagged a RM27.35 million sub-contract work from Kumpulan Liziz Sdn Bhd, who is the main contractor for the proposed Desaru Coast Marina, customs, immigration and quarantine (CIQ) complex and ferry terminal building in Desaru, Johor.
7240 BSMAF 1818
KUALA LUMPUR (Aug 14): Vertice Bhd is teaming up with Vizione Holdings Bhd to establish a 50:50 joint venture (JV), which will strengthen its core competencies in the construction industry.
7240 BSMAF 1818
PETALING JAYA: Vertice Bhd, formerly known as Voir Holdings Bhd , has entered into a memorandum of understanding (MoU) with Smuzcity Bhd to form a strategic alliance to collaborate for opportunities for qualified real properties to be considered for a structured smart hotel chain business.
PETALING JAYA: Vertice Bhd ’s wholly-owned subsidiary, Vertice Construction Sdn Bhd has accepted a sub-contract offer from Kumpulan Liziz Sdn Bhd for the road upgrading works of Federal Road 12 from Gambang, Pahang to Segamat, Johor for RM218.48mil. This is its biggest contract garnered to date.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...